{"id":"NCT00552175","sponsor":"Eli Lilly and Company","briefTitle":"A Study for the Treatment of Diabetic Peripheral Neuropathic Pain","officialTitle":"A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2007-11-01","resultsPosted":"2010-04-13","lastUpdate":"2010-04-13"},"enrollment":339,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathies"],"interventions":[{"type":"DRUG","name":"Duloxetine hydrochloride - 40 mg","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"Duloxetine hydrochloride - 60 mg","otherNames":["LY248686","Cymbalta"]}],"arms":[{"label":"Duloxetine 60","type":"EXPERIMENTAL"},{"label":"Duloxetine 40","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine if duloxetine can help patients with painful diabetic neuropathy.","primaryOutcome":{"measure":"Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg)","timeFrame":"Baseline, 12 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-1.61,"sd":0.18},{"arm":"Duloxetine 40 mg and 60 mg Combined","deltaMin":-2.47,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":25,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":167},"commonTop":["Somnolence","Nasopharyngitis","Nausea","Constipation","Aspartate aminotransferase increased"]}}